These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28378227)

  • 41. Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.
    Siemann DW; Chaplin DJ; Horsman MR
    Cancer Invest; 2017 Sep; 35(8):519-534. PubMed ID: 28872367
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epigenetic regulation and cancer (review).
    Chen QW; Zhu XY; Li YY; Meng ZQ
    Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials.
    Rüegg C; Meuwly JY; Driscoll R; Werffeli P; Zaman K; Stupp R
    Curr Mol Med; 2003 Dec; 3(8):673-91. PubMed ID: 14682490
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chromatin-modifying agents in anti-cancer therapy.
    Seidel C; Florean C; Schnekenburger M; Dicato M; Diederich M
    Biochimie; 2012 Nov; 94(11):2264-79. PubMed ID: 22627380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epigenetics in cancer therapy and nanomedicine.
    Roberti A; Valdes AF; Torrecillas R; Fraga MF; Fernandez AF
    Clin Epigenetics; 2019 May; 11(1):81. PubMed ID: 31097014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiogenesis research: guidelines for translation to clinical application.
    Folkman J; Browder T; Palmblad J
    Thromb Haemost; 2001 Jul; 86(1):23-33. PubMed ID: 11487011
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epigenetic therapy and chemosensitization in solid malignancy.
    Ronnekleiv-Kelly SM; Sharma A; Ahuja N
    Cancer Treat Rev; 2017 Apr; 55():200-208. PubMed ID: 28431263
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epigenetic drugs take on cancer.
    Kaiser J
    Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
    [No Abstract]   [Full Text] [Related]  

  • 49. Harnessing the potential of epigenetic therapy to target solid tumors.
    Ahuja N; Easwaran H; Baylin SB
    J Clin Invest; 2014 Jan; 124(1):56-63. PubMed ID: 24382390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review.
    Singh P; Tomar RS; Rath SK
    Mol Biol Rep; 2015 Nov; 42(11):1515-31. PubMed ID: 26033434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
    Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
    Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-angiogenesis in cancer therapy: Hercules and hydra.
    Bellou S; Pentheroudakis G; Murphy C; Fotsis T
    Cancer Lett; 2013 Sep; 338(2):219-28. PubMed ID: 23707856
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments.
    Schnekenburger M; Florean C; Dicato M; Diederich M
    Curr Top Med Chem; 2016; 16(7):745-76. PubMed ID: 26303418
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epigenetic targeting in pancreatic cancer.
    van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
    Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epigenetics in radiotherapy: where are we heading?
    Smits KM; Melotte V; Niessen HE; Dubois L; Oberije C; Troost EG; Starmans MH; Boutros PC; Vooijs M; van Engeland M; Lambin P
    Radiother Oncol; 2014 May; 111(2):168-77. PubMed ID: 24861629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
    Broxterman HJ; Georgopapadakou NH
    Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiogenesis inhibition for the improvement of photodynamic therapy: the revival of a promising idea.
    Weiss A; den Bergh Hv; Griffioen AW; Nowak-Sliwinska P
    Biochim Biophys Acta; 2012 Aug; 1826(1):53-70. PubMed ID: 22465396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful strategies in the discovery of small-molecule epigenetic modulators with anticancer potential.
    Bayo J; Dalvi MP; Martinez ED
    Future Med Chem; 2015; 7(16):2243-61. PubMed ID: 26510529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
    Nguyen TL; Wilson MG; Hiscott J
    Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.